A partial failure of membrane protein turnover may cause Alzheimer's disease

A new hypothesis

Kumar Sambamurti, Anitha Suram, Chitra Venugopal, Annamalai Prakasam, Yan Zhou, Debomoy Lahiri, Nigel H. Greig

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

The amyloid hypothesis has dominated the thinking in our attempts to understand, diagnose and develop drugs for Alzheimer's disease (AD). This article presents a new hypothesis that takes into account the numerous familial AD (FAD) mutations in the amyloid precursor protein (APP) and its processing pathways, but suggests a new perspective beyond toxicity of forms of the amyloid β-peptide (Aβ). Clearly, amyloid deposits are an invariable feature of AD. Moreover, although APP is normally processed to secreted and membrane-bound fragments, sAPPβ and CTFβ, by BACE, and the latter is subsequently processed by γ-secretase to Aβ and CTFγ, this pathway mostly yields Ab of 40 residues, and increases in the levels of the amyloidogenic 42-residue Aβ (Aβ42) are seen in the majority of the mutations linked to the disease. The resulting theory is that the disease is caused by amyloid toxicity, which impairs memory and triggers deposition of the microtubule associated protein, Tau, as neurofibrillary tangles. Nevertheless, a few exceptional FAD mutations and the presence of large amounts of amyloid deposits in a group of cognitively normal elderly patients suggest that the disease process is more complex. Indeed, it has been hard to demonstrate the toxicity of Aβ42 and the actual target has been shifted to small oligomers of the peptide, named Aβ derived diffusible ligands (ADDLs). Our hypothesis is that the disease is more complex and caused by a failure of APP metabolism or clearance, which simultaneously affects several other membrane proteins. Thus, a traffic jam is created by failure of important pathways such as γ-secretase processing of residual intramembrane domains released from the metabolism of multiple membrane proteins, which ultimately leads to a multiple system failure. In this theory, toxicity of Aβ42 will only contribute partially, if at all, to neurodegeneration in AD. More significantly, this theory would predict that focussing on specific reagents such as γ-secretase inhibitors that hamper metabolism of APP, may initially show some beneficial effects on cognitive performance by elimination of acutely toxic ADDLs, but over the longer term may exacerbate the disease process by reducing membrane protein turnover.

Original languageEnglish (US)
Pages (from-to)81-90
Number of pages10
JournalCurrent Alzheimer Research
Volume3
Issue number1
DOIs
StatePublished - Feb 2006
Externally publishedYes

Fingerprint

Amyloid beta-Protein Precursor
Alzheimer Disease
Membrane Proteins
Amyloid Precursor Protein Secretases
Amyloid
Amyloid Plaques
Mutation
Ligands
Neurofibrillary Tangles
Microtubule-Associated Proteins
Poisons
Peptides
Membranes
Pharmaceutical Preparations

Keywords

  • AICD
  • Alzheimer's disease
  • Dementia
  • Neurodegeneration
  • Oligomers

ASJC Scopus subject areas

  • Biological Psychiatry
  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

A partial failure of membrane protein turnover may cause Alzheimer's disease : A new hypothesis. / Sambamurti, Kumar; Suram, Anitha; Venugopal, Chitra; Prakasam, Annamalai; Zhou, Yan; Lahiri, Debomoy; Greig, Nigel H.

In: Current Alzheimer Research, Vol. 3, No. 1, 02.2006, p. 81-90.

Research output: Contribution to journalArticle

Sambamurti, Kumar ; Suram, Anitha ; Venugopal, Chitra ; Prakasam, Annamalai ; Zhou, Yan ; Lahiri, Debomoy ; Greig, Nigel H. / A partial failure of membrane protein turnover may cause Alzheimer's disease : A new hypothesis. In: Current Alzheimer Research. 2006 ; Vol. 3, No. 1. pp. 81-90.
@article{7e9f94f797d54017b608891db11e26a4,
title = "A partial failure of membrane protein turnover may cause Alzheimer's disease: A new hypothesis",
abstract = "The amyloid hypothesis has dominated the thinking in our attempts to understand, diagnose and develop drugs for Alzheimer's disease (AD). This article presents a new hypothesis that takes into account the numerous familial AD (FAD) mutations in the amyloid precursor protein (APP) and its processing pathways, but suggests a new perspective beyond toxicity of forms of the amyloid β-peptide (Aβ). Clearly, amyloid deposits are an invariable feature of AD. Moreover, although APP is normally processed to secreted and membrane-bound fragments, sAPPβ and CTFβ, by BACE, and the latter is subsequently processed by γ-secretase to Aβ and CTFγ, this pathway mostly yields Ab of 40 residues, and increases in the levels of the amyloidogenic 42-residue Aβ (Aβ42) are seen in the majority of the mutations linked to the disease. The resulting theory is that the disease is caused by amyloid toxicity, which impairs memory and triggers deposition of the microtubule associated protein, Tau, as neurofibrillary tangles. Nevertheless, a few exceptional FAD mutations and the presence of large amounts of amyloid deposits in a group of cognitively normal elderly patients suggest that the disease process is more complex. Indeed, it has been hard to demonstrate the toxicity of Aβ42 and the actual target has been shifted to small oligomers of the peptide, named Aβ derived diffusible ligands (ADDLs). Our hypothesis is that the disease is more complex and caused by a failure of APP metabolism or clearance, which simultaneously affects several other membrane proteins. Thus, a traffic jam is created by failure of important pathways such as γ-secretase processing of residual intramembrane domains released from the metabolism of multiple membrane proteins, which ultimately leads to a multiple system failure. In this theory, toxicity of Aβ42 will only contribute partially, if at all, to neurodegeneration in AD. More significantly, this theory would predict that focussing on specific reagents such as γ-secretase inhibitors that hamper metabolism of APP, may initially show some beneficial effects on cognitive performance by elimination of acutely toxic ADDLs, but over the longer term may exacerbate the disease process by reducing membrane protein turnover.",
keywords = "AICD, Alzheimer's disease, Dementia, Neurodegeneration, Oligomers",
author = "Kumar Sambamurti and Anitha Suram and Chitra Venugopal and Annamalai Prakasam and Yan Zhou and Debomoy Lahiri and Greig, {Nigel H.}",
year = "2006",
month = "2",
doi = "10.2174/156720506775697142",
language = "English (US)",
volume = "3",
pages = "81--90",
journal = "Current Alzheimer Research",
issn = "1567-2050",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - A partial failure of membrane protein turnover may cause Alzheimer's disease

T2 - A new hypothesis

AU - Sambamurti, Kumar

AU - Suram, Anitha

AU - Venugopal, Chitra

AU - Prakasam, Annamalai

AU - Zhou, Yan

AU - Lahiri, Debomoy

AU - Greig, Nigel H.

PY - 2006/2

Y1 - 2006/2

N2 - The amyloid hypothesis has dominated the thinking in our attempts to understand, diagnose and develop drugs for Alzheimer's disease (AD). This article presents a new hypothesis that takes into account the numerous familial AD (FAD) mutations in the amyloid precursor protein (APP) and its processing pathways, but suggests a new perspective beyond toxicity of forms of the amyloid β-peptide (Aβ). Clearly, amyloid deposits are an invariable feature of AD. Moreover, although APP is normally processed to secreted and membrane-bound fragments, sAPPβ and CTFβ, by BACE, and the latter is subsequently processed by γ-secretase to Aβ and CTFγ, this pathway mostly yields Ab of 40 residues, and increases in the levels of the amyloidogenic 42-residue Aβ (Aβ42) are seen in the majority of the mutations linked to the disease. The resulting theory is that the disease is caused by amyloid toxicity, which impairs memory and triggers deposition of the microtubule associated protein, Tau, as neurofibrillary tangles. Nevertheless, a few exceptional FAD mutations and the presence of large amounts of amyloid deposits in a group of cognitively normal elderly patients suggest that the disease process is more complex. Indeed, it has been hard to demonstrate the toxicity of Aβ42 and the actual target has been shifted to small oligomers of the peptide, named Aβ derived diffusible ligands (ADDLs). Our hypothesis is that the disease is more complex and caused by a failure of APP metabolism or clearance, which simultaneously affects several other membrane proteins. Thus, a traffic jam is created by failure of important pathways such as γ-secretase processing of residual intramembrane domains released from the metabolism of multiple membrane proteins, which ultimately leads to a multiple system failure. In this theory, toxicity of Aβ42 will only contribute partially, if at all, to neurodegeneration in AD. More significantly, this theory would predict that focussing on specific reagents such as γ-secretase inhibitors that hamper metabolism of APP, may initially show some beneficial effects on cognitive performance by elimination of acutely toxic ADDLs, but over the longer term may exacerbate the disease process by reducing membrane protein turnover.

AB - The amyloid hypothesis has dominated the thinking in our attempts to understand, diagnose and develop drugs for Alzheimer's disease (AD). This article presents a new hypothesis that takes into account the numerous familial AD (FAD) mutations in the amyloid precursor protein (APP) and its processing pathways, but suggests a new perspective beyond toxicity of forms of the amyloid β-peptide (Aβ). Clearly, amyloid deposits are an invariable feature of AD. Moreover, although APP is normally processed to secreted and membrane-bound fragments, sAPPβ and CTFβ, by BACE, and the latter is subsequently processed by γ-secretase to Aβ and CTFγ, this pathway mostly yields Ab of 40 residues, and increases in the levels of the amyloidogenic 42-residue Aβ (Aβ42) are seen in the majority of the mutations linked to the disease. The resulting theory is that the disease is caused by amyloid toxicity, which impairs memory and triggers deposition of the microtubule associated protein, Tau, as neurofibrillary tangles. Nevertheless, a few exceptional FAD mutations and the presence of large amounts of amyloid deposits in a group of cognitively normal elderly patients suggest that the disease process is more complex. Indeed, it has been hard to demonstrate the toxicity of Aβ42 and the actual target has been shifted to small oligomers of the peptide, named Aβ derived diffusible ligands (ADDLs). Our hypothesis is that the disease is more complex and caused by a failure of APP metabolism or clearance, which simultaneously affects several other membrane proteins. Thus, a traffic jam is created by failure of important pathways such as γ-secretase processing of residual intramembrane domains released from the metabolism of multiple membrane proteins, which ultimately leads to a multiple system failure. In this theory, toxicity of Aβ42 will only contribute partially, if at all, to neurodegeneration in AD. More significantly, this theory would predict that focussing on specific reagents such as γ-secretase inhibitors that hamper metabolism of APP, may initially show some beneficial effects on cognitive performance by elimination of acutely toxic ADDLs, but over the longer term may exacerbate the disease process by reducing membrane protein turnover.

KW - AICD

KW - Alzheimer's disease

KW - Dementia

KW - Neurodegeneration

KW - Oligomers

UR - http://www.scopus.com/inward/record.url?scp=33645846948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645846948&partnerID=8YFLogxK

U2 - 10.2174/156720506775697142

DO - 10.2174/156720506775697142

M3 - Article

VL - 3

SP - 81

EP - 90

JO - Current Alzheimer Research

JF - Current Alzheimer Research

SN - 1567-2050

IS - 1

ER -